|
Senior Member
Join Date: Aug 2010
Location: New York, New York
Posts: 1,580
|
My Update on 09-093 Trial
Dear Friends,
Here's my update for the 09-093 trial:
The 09-093 trial I have been on for one year has concluded and I remain NED. It was a hard won NED, but no regimen is easy. This trial started with Taxol, T-DM1 and Perjeta. I tolerated it quite well, but the infusions were five hours long when the three drugs were given together, and ultimately, during month three, Taxol had to be dropped due to severe side effects: 1) an SMA, which is an intestinal aneurysm (and it contained a blood clot), 2) near total loss of vision in my right eye which was neuropathy of the optical nerve and, 3) general neuropathy of hands and feet. After the Taxol was dropped, we continued on with the T-DM1 and Perjeta for the next nine months. I needed to use blood thinners for a time and learned my blood was too thin when a nosebleed landed me in the hospital with my face packed for for four days. We stopped the blood thinners. My vision returned and to everyone's amazement, the SMA was gone as well. This is nothing short of a miracle. Arteries just don't dilate and un-dilate.
This trial also required weekly bloodwork and CT scans, sometimes combined with PETs every six weeks. The hardest part has been the hit blood platelets take with T-DM1. Also, I take a dose of 2.4 mg/kg weekly. Part of the study was to determine whether there's more efficacy in weekly or tri-weekly doses.
So, on Wednesday, I had a CT, brain MRI, bone scan and echo done, as you have to repeat the inclusion criteria to continue on the extended study. I had such jitters waiting for the results--we all know how that feels. But, all is clear and I must forge on. The hardest part is the neuropathy, which I have at Grade 2. T-DM1 contains agents that can cause taxane-like side effects. I'm just happy to have my sight back.
Now, I will have bloods done every three weeks and scans every four months. A welcome change indeed. By participating in this trial, I hope I laid some groundwork and have given scientists and doctors and co-patients much-needed information.
I, for one, have been overwhelmed in recent months by the friends I have lost, with special mention to those on our list. I remember Jackie's father's words (no rest for a soldier's daughter) and my own father's words (you are going to be good) in their honor. None of us should have to endure the pain, the interruption of our lives, the terror of scan and test results.
Sent with love for the holiday season and beyond,
Happy 2013,
Karen
__________________
World Trade Center Survivor (56th Floor/North Tower): 14 years and still just like yesterday.
Graves Disease, became Euthyroid via Radioactive Iodine, June 2001.
Thyroid Eye Disease. 2003. Decompression surgery in 2009; eyelid lowering surgery in 2010.
Diagnosed: June 2010, liver mets. ER-/PR+10%; HER2+++.
July 2010: Begin Taxol/Herceptin. Eliminate sugar from diet. No surgery or radiation.
January 2011: NED
April 2011: Progression in liver only. Other previous affected areas eradicated. Stop Taxol/Herceptin after 32 infusions.
May 2011: Brain MRI: clear.
May 2011: Begin Tykerb daily, Xeloda twice per day for one week on, one week off, and Herceptin.
November 2011: Progression in liver. All other tumors remain eradicated.
December 2011: BEGIN TRIAL #09-093 Taxol, MCC-DM1 (T-DM1), Perjeta.
Trial requires scans every six weeks, bloodwork and infusions weekly.
Brain MRI: clear.
January 2012: NED. Liver mets, good riddance!
March 2012: NED. Developed SMA (rare blood clot) in intestinal artery and loss of sight in right eye due to optical nerve neuropathy. Resolved when Taxol removed this month.
Continue Protocol of T-DM1 weekly and Perjeta every 3 weeks.
May 2012: NED.
June 2012: Brain MRI: clear.
June-December 2012: NED.
December 2012: TRIAL CONCLUDED; ENTER TRIAL EXTENSION #09-037. CT, Brain MRI, bone scan: clear. NED.
January-March 2013: NED.
June 2013: Brain MRI: clear. CEA upticking; CT shows new met on liver.
July 3, 2013: DISASTER STRIKES during liver ablation: sloppy surgeon cuts intercostal artery and I bleed out, lose 3.5 liters of blood, have major hemothorax, and collapsed lung requiring emergency resuscitative thoracotomy, lung surgery, rib rearrangement and cutting deep connective tissue, transfusion. Ablation incomplete. This life-saving procedure would end up causing me unforgiving pain with every movement I make, permanently, otherwise known as forever.
July 26, 2013: Try Navelbine/Herceptin. Body too weak after surgery and transfusion. Fever. CEA: Normal.
August 16, 2016: second dose Navelbine/Herceptin; CEA: Normal. Will skip doses. Watching and waiting.
September 2013: NED, Herceptin only. CEA: Normal. Started Arimidex.
October-November 2013: NED. Herceptin and Arimidex. CEA, CA125, 15-3: Normal.
December 2013: Something brewing. PET lights up on little spot on liver; CEA upward trend, just outside normal. PET and triphasic liver scan confirm Little Met. Restart Perjeta with Herceptin, stay on Arimidex. Genomic sequencing completed for future treatments, if necessary.
January 2014: Ablate Little Met on the 6th. Happy New Year.
March 2014: Brain MRI: clear. PET/CT reveal liver mets return; new lung mets. This is not funny.
March 2014: BEGIN TRIAL #10-005 A(11)-Temsirolimus plus Neratinib.
April 2014: Genomic testing indicated they could work, they did not. Very strange drug combo for me, felt weird.
April 2014: Started Navelbine and Herceptin. Needed something tried and true, but had significant progression.
June 2014: Doxil and Herceptin.
July 2014: Progression. Got nothing out of it. Brain: NED.
July 2014: Add integrative medical hematologist-oncologist to my team. Begin supplements. These are tumor-busting, immune system boosters. Add glutathione, lysine and taurine IV infusions every three weeks.
July 2014: Begin Gemzar, Herceptin & Perjeta. Happy.
August 2014: ECHO perfect.
January 2015: Begin weekly Vitamin D Analog infusions. 25 mcg. via port.
February 2015: CT: stable.
April 2015: Gem working, but not 100%. Looking into immunotherapy. Finally, treatments for the 21st century!
April 2015: Penn Medicine. Dendritic cell immunotherapy.
|